NASDAQ:SYNH - Syneos Health Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$48.75 +0.10 (+0.21 %)
(As of 06/22/2018 03:07 PM ET)
Previous Close$49.15
Today's Range$48.45 - $49.20
52-Week Range$31.10 - $60.70
Volume31,381 shs
Average Volume752,040 shs
Market Capitalization$5.03 billion
P/E Ratio25.23
Dividend YieldN/A
Beta0.83
Syneos Health logoSyneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300

Debt

Debt-to-Equity Ratio1.01
Current Ratio1.09
Quick Ratio1.09

Price-To-Earnings

Trailing P/E Ratio25.23
Forward P/E Ratio20.66
P/E Growth1.18

Sales & Book Value

Annual Sales$2.67 billion
Price / Sales1.88
Cash Flow$3.7674 per share
Price / Cash12.94
Book Value$28.97 per share
Price / Book1.68

Profitability

EPS (Most Recent Fiscal Year)$1.94
Net Income$-138,460,000.00
Net Margins-5.50%
Return on Equity8.79%
Return on Assets3.53%

Miscellaneous

Employees21,000
Outstanding Shares102,780,000

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

How were Syneos Health's earnings last quarter?

Syneos Health Inc (NASDAQ:SYNH) announced its earnings results on Wednesday, May, 9th. The company reported $0.55 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.51 by $0.04. The company earned $761 million during the quarter, compared to the consensus estimate of $767.24 million. Syneos Health had a negative net margin of 5.50% and a positive return on equity of 8.79%. Syneos Health's quarterly revenue was up 201.9% on a year-over-year basis. View Syneos Health's Earnings History.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Syneos Health.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY18 earnings guidance on Wednesday, May, 9th. The company provided earnings per share guidance of $2.52-$2.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.63. The company issued revenue guidance of $3.235-$3.340, compared to the consensus revenue estimate of $3.24 billion.

What price target have analysts set for SYNH?

10 brokerages have issued 12-month price targets for Syneos Health's shares. Their forecasts range from $41.00 to $65.00. On average, they expect Syneos Health's stock price to reach $50.7778 in the next twelve months. View Analyst Ratings for Syneos Health.

Who are some of Syneos Health's key competitors?

Who are Syneos Health's key executives?

Syneos Health's management team includes the folowing people:
  • Mr. Alistair MacDonald, CEO & Director (Age 48)
  • Dr. Michael Gibertini Ph.D., Pres of Clinical Devel. for Therapeutic Bus. Units (Age 60)
  • Mr. Jason M. Meggs, Exec. VP, Interim CFO & Principal Accounting Officer (Age 42)
  • Dr. Judith Ng-Cashin, Chief Scientific Officer
  • Ms. Rachel Stahler, Chief Information Officer (Age 42)

Has Syneos Health been receiving favorable news coverage?

News coverage about SYNH stock has been trending somewhat positive on Friday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syneos Health earned a media sentiment score of 0.17 on Accern's scale. They also assigned media coverage about the company an impact score of 45.71 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include Lee Thomas H Partners LP (24.25%), BlackRock Inc. (6.81%), Dimensional Fund Advisors LP (1.72%), Redmile Group LLC (1.48%), Cooke & Bieler LP (1.30%) and Northern Trust Corp (1.01%). Company insiders that own Syneos Health stock include Alistair Macdonald, Avista Capital Partners Ii Gp,, Christopher L Gaenzle, D Jamie Macdonald, David F Burgstahler, Gregory S Rush, Robert W Breckon and Teachers Pension Plan Ontario. View Institutional Ownership Trends for Syneos Health.

Which major investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including American International Group Inc.. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, Christopher L Gaenzle and Gregory S Rush. View Insider Buying and Selling for Syneos Health.

Which major investors are buying Syneos Health stock?

SYNH stock was bought by a variety of institutional investors in the last quarter, including Lee Thomas H Partners LP, BlackRock Inc., Dimensional Fund Advisors LP, Redmile Group LLC, Cooke & Bieler LP, Northern Trust Corp, The Manufacturers Life Insurance Company and GW&K Investment Management LLC. View Insider Buying and Selling for Syneos Health.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $48.70.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $5.03 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.

How can I contact Syneos Health?

Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]


MarketBeat Community Rating for Syneos Health (SYNH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.